The International Olympic Committee (IOC) Consensus Statement on Periodic Health Evaluation of Elite Athletes: March 2009

The Olympic Games is the largest sport event in the world. In Beijing, 10500 athletes competed, selected from a large group of elite athletes in 204 countries. Sports participation on the elite level, aside from winning medals, fame and other rewards, is also important from a health perspective. There is no longer any doubt that regular physical activity reduces the risk of premature mortality in general, and of coronary heart disease, hypertension, colon cancer, obesity, and diabetes mellitus in particular. The question is whether the health benefits of sports participation outweigh the risk of injury and long-term disability, especially in high-level athletes. Sarna et al (2000) have studied the incidence of chronic disease and life expectancy of former male world-class athletes from Finland in endurance sports, power sports and team sports. The overall life expectancy was longer in the high-level athlete compared to a reference group (75.6 versus 69.9 years). The same group also showed that the rate of hospitalization later in life was lower for endurance sports and power sports compared to the reference group (Kujala 1996). This resulted from a lower rate of hospital care for heart disease, respiratory disease and cancer. However, the athletes were more likely to have been hospitalized for musculoskeletal disorders. Thus, the evidence suggests that although there is a general health benefit from sports participation, injuries represent a significant side effect.One priority of the International Olympic Committee (IOC) is to protect the health of the athlete. During recent years, prevention of injuries and illnesses has been high on the IOC agenda. During the Athens Games an injury surveillance system was applied for all team sports (Junge et al 2006). During the Beijing Games, the IOC ran, for the first time, an injury surveillance system covering all the athletes, showing a 10% incidence of injuries (Junge et al 2008). In Vancouver and London the surveillance system will include disease conditions as well. The surveillance studies are prerequisites for providing evidence for health development in sports as well as for developing prevention programs. Another method to decrease injuries and diseases in the elite athlete is to perform a pre-participation examination (PPE) or periodic health evaluation (PHE) of all elite athletes (Junge at al 2009). PHE in various forms have been available for many years, but a recent analysis (Wingfield et al 2004) has questioned the efficacy of PHEs in detecting serious problems in the elite athlete.In March 2009, the IOC assembled an expert group to discuss the current state of health evaluations for athletes, aiming to provide recommendations for a practical PHE for the elite athlete, as well as to outline the need for further research. The task of the group was to review the benefits as well as potential negative effects of PHE at the elite sport level. The group did not take any position as to whether PHE should be recommended as compulsory for participation in sport. That is for the relevant sports authorities to decide.The PHE can serve many purposes. It includes a comprehensive assessment of the athlete's current health status and risk of future injury or disease and, typically, is the entry point for medical care of the athlete. The PHE also serves as a tool for continuous health monitoring in athletes. Recent advances in this field relate to: (i) data on sudden cardiac death and other noncardiac medical problems, and the detection of risk factors and groups; (ii) a consensus conference on concussion; (iii) data on eating disorders and (iv) data on risk factors for musculoskeletal injuries. This paper addresses each of these advances in more detail after a discussion on the purpose of a PHE and the evidence we have supporting the different components of the PHE.In a narrow sense, the main purpose of the PHE is to screen for injuries or medical conditions that may place an athlete at risk for safe participation. Athletes may be affected by conditions that do not have overt symptoms and that can only be detected by periodic health evaluations. One example is cardiovascular abnormalities, such as hypertrophic cardiomyopathy, arrythmogenic right ventricular cardiomyopathy or congenital coronary arteries anomalies. These are typically silent until a potentially fatal arrhythmia occurs, but may in some cases be detected through a careful cardiovascular examination.Screening is a strategy used in a population to detect a disease in individuals without signs or symptoms of that disease. The intention is to identify pathologic conditions early, thus enabling earlier intervention and management in the hope of reducing future morbidity and mortality. Although screening may lead to an earlier diagnosis, not all screening programs have been shown to benefit the person being screened.To ensure that screening programs confer the intended benefit, the World Health Organisation published what have become known as the Wilson-Jungner criteria for appraising a screening programme (Wilson &amp; Jungner 1968). The main criteria are that the condition being screened for is an important health problem (depends not just on how serious the condition is, but also how common it is), that there is a detectable early stage, that treatment at an early stage is of more benefit than at a later stage and that a suitable test is available to detect disease in the early stage.From a public health perspective, there is insufficient evidence to date to mandate any specific screening tests for elite athletes apart from those recommended for the general population. This is mainly the consequence of the low risk of serious conditions in this population. An important limitation is also the lack of suitable screening tests; such tests must be reliable (repeatable, good inter-observer agreement), sensitive (detects all those with increased risk), specific (detects only those with increased risk), affordable (ideally cheap, easy to perform, widely available), acceptable to the screening population and subject to quality assurance.However, the PHE may serve other purposes than just screening athletes for future health problems. One obvious goal is to ensure that current health problems are managed appropriately and, ultimately, to determine whether an athlete is medically suitable to engage in a particular sport or event. Even elite athletes with easy access to medical care do not always seek medical attention for injuries or disease, despite having significant symptoms.Some silent conditions are common and, although not severe from a health perspective, may influence sports performance. An example of this is mild iron deficiency, which is common in female athletes. Periodic health evaluations and ongoing monitoring represent an opportunity to diagnose and manage such conditions. They also provide an opportunity to identify conditions that are barriers to performance. An example is astigmatism, which can be detected on a simple test of visual acuity. Another important function of periodic health evaluations is that they allow the athlete an opportunity to establish a relationship with the health personnel who will be involved in providing continuing care.Finally, the PHE also represents an opportunity to look for characteristics which may put the elite athlete at risk for future injury or disease. However, as mentioned above, there is limited direct evidence to suggest that it is possible to predict future outcomes based on the PHE. Nevertheless, there is evidence in some areas, such as injury risk factor assessment (Bahr &amp; Engebretsen 2009), that holds future promise and warrants investigation related to the PHE. Depending on the sport and the age, ethnic origin and gender of the athlete, it may be prudent to include an assessment of specific risk factors in the PHE.It is important to address and balance the ethical and legal aspects of the PHE in order to help protect the rights and responsibilities of athletes, physicians, sporting organizations and other persons concerned. In the context of designing and implementing a PHE, the following considerations need to be taken into account:In many settings, the PHE is used to offer medical clearance to participate in sport and is seen as a one-time certification for future involvement in elite sport. However, the evaluation of the athlete's health should ideally be seen as a dynamic, ongoing process.While many aspects of the PHE will be common to all elite athletes, it should be tailored to be gender, age, race, culture and sport specific when appropriate. If any injury or medical condition is identified, it should be managed in a manner consistent with the existing standards of medical care. If warranted, this may involve referral to the appropriate specialists for further evaluation and management. It should be noted that the PHE is also the time that medications or nutritional products in use or prescribed should be reviewed to determine if a Therapeutic Use Exemption (TUE) application to the World Anti Doping Association (WADA) is needed.The timing of the PHE should ideally allow for sufficient time for management of any injuries or medical problems well before major competitions. For example, it is preferable to conduct a PHE during the off-season so that rehabilitation or other treatment can restore the athlete to optimal health before facing maximal physical stress.As the PHE is the only contact that many elite athletes will have with medical personnel, it should be seen as an opportunity for education regarding other health risks and health-related behavior.The following document is laid out in sections that correspond to the various areas of evaluation appropriate to the elite athlete.The scope of the cardiovascular PHE is to detect potentially lethal cardiovascular disease in elite athletes and start appropriate management to reduce the risk for sudden cardiac death and/or disease progression in a timely fashion.Regular participation in training and athletic competition is associated with an increased risk for sudden cardiac death (SCD), with an average relative risk for athletes of 2.8 times compared to their nonathletic counterpart (Corrado et al 2003). It is worthy to note, however, that sport is not per se the cause for greater incidence of SCD. It is the combination of intensive physical exercise in athletes with underlying cardiovascular disease, which can trigger ominous arrhythmias leading to cardiac arrest. The relative risk of sport participation is different according to the underlying disease, and it is greatest in case of cardiomyopathies (such as hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy) or congenital coronary arteries anomalies (Corrado et al 2003).The vast majority of the athletes dying suddenly do not experience premonitory symptoms (Maron 2003); therefore, the PHE represents the only strategy capable to identify athletes with silent cardiac disease, and allow appropriate management to reduce the risk of SCD and disease progression. Identifying asymptomatic athletes with underlying cardiovascular disease through the PHE is important because SCD could be prevented by lifestyle modification, including (when necessary) restriction from competitive sports activity, but also prophylactic treatment by drugs, implantable cardioverter defibrillator (ICD) or other therapeutic options. Athletes carrying an increased cardiac risk may have a favourable long-term outcome thanks to timely identification and appropriate clinical management (Corrado et al 1998).Recent scientific evidence supports the role of ECG in reducing mortality in screened athletes (Corrado et al 2006). This concept is based on the recognition that ECG is abnormal in most individuals with hypertrophic cardiomyopathy (up to 90%) and arrhythmogenic right ventricular cardiomyopathy (up to 80%). The ECG can also identify athletes with WPW syndrome and ion channel diseases, such as Lènegre conduction disease, long or short QT syndromes, and Brugada syndrome (Corrado et al 2007, Lawless and Best 2008). However, criticism has been voiced related to available data on the use of ECG in elite athletes due to the lack of an unscreened athletic control group. A comparison of athletes screened with ECG vs. athletes non-screened will require two matched large athlete populations (several thousand athletes, in consideration of the low incidence of cardiomyopathies) undergoing long-term follow-up (at least two decades, due to the young age of athletes at initial evaluation).It has been demonstrated that adding a 12-lead ECG examination to history and physical examination results in a substantial increase in the ability to identify potentially lethal heart disorders (Corrado et al 2007, Lawless and Best 2008) and this strategy has been endorsed in “The Lausanne Recommendations” (Bille et al 2006) and the European Society of Cardiology recommendations (Corrado et al 2005). However, it is not currently recommended by the American Heart Association (Chaitman 2007, Myerburg and Vetter 2007).The 12-lead ECG should be recorded on a non-training day, during rest, according to best clinical practice. Interpretation of the ECG abnormalities can be categorized according to the criteria defined by Corrado et al (2008) into two groups: 1) the most common in trained athletes (sinus bradycardia, first degree AV block, notched QRS in V1 or incomplete right bundle branch block, isolated QRS voltage criteria for LV hypertrophy) consistent with athlete's age, ethnical origin and level of athletic conditioning, and that do not require additional testing; 2) all other less common ECG abnormalities should be further evaluated to exclude cardiovascular disease (Fig 1).At present, there is no agreement regarding the need for routine use of echocardiography in the PHE. Neither is there a role for routine use of other imaging or invasive testing. However, in the presence of abnormal findings either at history, physical examination or 12-lead ECG, additional testing should be performed in order to confirm (or exclude) cardiovascular disease. In most instances, echocardiography is the first-line test, but other imaging modalities (such as cardiac magnetic resonance) or invasive testing, when necessary, may be pursued. In adult athletes (&gt;35 years) exercise ECG testing in the context of PHE is efficient to detect otherwise unsuspected cardiac abnormalities (Sofi 2008) and is currently recommended for elite athletes with increased cardiovascular risk profile (Thompson 2007).The IOC PHE Consensus Group recommends that any athlete identified with a CV abnormality should be managed according to the current, widely accepted clinical recommendations, i.e., Bethesda Conference #36 and ESC recommendations (Maron and Zipes 2005, Pelliccia et al 2005). The group acknowledges that identification of cardiac disease in an athlete represents a challenging question regarding the ethical, medical and legal consequence with particular regard to the need for disqualification from competition. However, there is scientific evidence that preventing athletes with specific cardiovascular abnormality from regular training and competition is an efficient strategy for preventing SCD (Corrado et al 1998, Biffi et al 2004). Unnecessary exclusion from participation of competitive athletes with non lethal diseases is a problem. Therefore, there is a need for a common agreement of sports eligibility guidelines and management of competitive athletes with cardiovascular diseases in the future (Pelliccia et al 2008). The main goal should be to reduce the number of unnecessary disqualifications and to adapt (rather than restrict) sports activity in relation to the specific cardiovascular risk.Finally, we recognize that young competitive athletes (&lt;18 years) require specific expertise in the evaluation, interpretation of findings and management.The sport organizations together with scientific sport societies should encourage and support educational activities intended to enhance the knowledge and skill of physicians involved in the cardiology part of the PHE process.Although there are issues of debate regarding wide-scale mandatory use of the ECG for athlete screening (Chaitman 2007, Pelliccia 2008), there is sufficient evidence to justify a staged implementation with evaluation to assess the properties of the test (sensitivity, specificity, predictive value) in a variety of sporting populations. Staged implementation would provide a natural control group to measure differences in outcome between ECG screened and unscreened groups. Finally, the mortality effects of a screening program documented in Italy need to be replicated in other ethnic populations where the underlying disease conditions may differ from those seen in Italy.The sport organizations and scientific sport societies should encourage research that could expand our current knowledge and data base regarding the mechanisms and strategies to prevent SCD in competitive athletes.To date, the main elements of the PHE have been to screen elite athletes for possible risk for sudden cardiovascular death (Beckerman et al 2004, Corrado et al 2005), musculoskeletal injury (Garrick 2004), and head injury (McCrory 2004). Furthermore, elements of the PHE that focus on non-cardiac medical conditions have to date been confined to hematological conditions (Fallon 2004), lung disease, particularly exercise-induced bronchoconstriction (Holzer and Brukner 2004), and specific medical concerns of the female athlete (Rumball and Lebrun 2004).However, sports physicians who regularly perform medical assessments on elite athletes, as well as members of the medical team that accompany athletes to the Olympic Games and other international sports events, commonly encounter medical conditions that are non-injury related, and are of a non-cardiac nature (Derman 2003, Derman 2004, Grissom et al 2006).In one study, it was reported that 50% of the 1804 athletes seen at the multipurpose medical facility at the 1996 Olympic Games were treated for non-injury related illnesses (Wetterhall et al 1998). In another study conducted in the athlete medical clinic during the 2002 Winter Olympic Games, medical diagnoses, notably respiratory conditions, were more commonly reported than traumatic conditions (Grissom et al 2002). Furthermore, in two other studies, over 50% of the medical consultations in a participating team during two Olympic Games were non-injury related (Derman 2003, Derman 2004). It is important to note that the frequency of cardiac-related medical consultations reported in these two studies was very low (Derman 2003, Derman 2004).Therefore, medical conditions in systems other than the cardiovascular system are very common in elite athletes. These conditions can occur immediately before competitions, during periods of training in preparation for competitions, and after competitions. In two reports, the frequency of medical conditions reported in athletes during the Olympic Games has been documented (Table 1). These data indicate that medical conditions, other than cardiovascular conditions, are common in elite athletes, yet these conditions have not received much attention in a PHE. A spectrum of medical conditions can occur in athletes across a number of medical systems (Table 2) and these can be identified during a PHE (Rifat et al 1995, Lively 1999). Finally, a number of these conditions are transient and can be treated. Therefore, clearance for sports participation when athletes from these conditions is an ongoing and ongoing monitoring and purpose of this is to 1) review the evidence base for including elements in the PHE that focus on non-cardiac medical conditions, 2) elements in the medical history, physical examination and that could be in a PHE to identify significant non-cardiac medical conditions, and suggest future for research in this is very data available on the of assessment for non-cardiac medical conditions in a PHE. for the of screening tests to identify non-cardiac medical conditions in a PHE is limited to expert and case However, the identification of some non-cardiac medical conditions is in the medical history, physical examination and profile of of existing PHE recommendations et al 2004, et al 2004, Brukner et al 2004, et al 2007, and 2005, et al The evidence base for including screening to identify non-cardiac medical conditions in a will be reviewed for including an assessment of the system in a PHE is that respiratory symptoms that are of are common in athletes et al 2008). the time of a PHE, these symptoms can be identified, and the clinical together with tests can be used to confirm the of et al 2008). The of in athletes is high and from in sports to in sports et al et al 2008). Furthermore, during a PHE, respiratory conditions other than that can also to respiratory symptoms in athletes can be identified et al main for including routine hematological assessment during a PHE is based on the than of iron in athletes, particularly female athletes (Fallon 2004, et al and 2005, 2007, et al et al et al 2008). An additional is to determine if the athlete has or and to identify other illnesses such as (Fallon 2004). It is that hematological testing has been as a tool for as well et al 2002). The of a on routine hematological screening is in compared with male athletes (Fallon 2004, 2007, et al for including assessments in the PHE to identify particularly in elite athletes is based on the that 1) than of conditions has been in elite athletes et al et al et al 2) athletes could be to a variety of at different where international take place et al and and chronic could in morbidity and also reduce athletic et al 2003).The to disease in a PHE is based on a number of important it is that during training and immediately following competitions, there is evidence of in athletes that could to disease et al 2006). is a to participation in sports because of the risk of injury and in some cases increased risk of of the to athletes et al and 2007, and the PHE an opportunity to assess whether an athlete has been conditions, including those that may be associated with international to specific There are a number of illnesses that could be when a PHE and these have been reviewed et al and 2007).The for including the and assessment in a PHE is based on the high incidence medical consultations during international that are related to this system in elite athletes (Table 1). Furthermore, the common illnesses in the system of athletes are et al et al and respiratory (Grissom et al et al et al 2006). The for including this spectrum of conditions in PHE has been for including a assessment in the PHE is that disorders are very common in athletes 2003). Furthermore, participation in sports may athletes to conditions and there is a risk of of conditions during sports 2008). Therefore, clearance to may have to be if athletes from some for including an assessment of the system in the PHE is not based on However, it is known that 1) and disease can be and 2) conditions such as asymptomatic and are when screening in athletes is conducted and 2008). Although these conditions may not be they do require further evaluation to exclude underlying for including an assessment of the system in the PHE is that symptoms are very common in athletes endurance during sports participation and 2008). of significant underlying disease is important in athletes, particularly those that regularly from symptoms during exercise and 2008). Furthermore, conditions are also when with athletes to international (Derman 2003, Derman for including assessment of conditions in the PHE of athletes is that conditions are common (McCrory 2008) and can include a variety of different conditions such as and Furthermore, although can occur in including athletes. It has been that the PHE should include screening for the risk factors of in young athletes (McCrory for routine to determine if elite athletes have underlying and disease is 1) that these conditions do occur in elite 2) one of the more common conditions in elite athletes is diabetes mellitus Olympic athletes therapeutic use for the use of in the Olympic Games et al and elite athletes with existing and disease may require and because they may use could control et al for including assessment in the PHE is that conditions, particularly visual have been reported in of athletes undergoing a PHE (Rifat et al 1995, Lively and 2003). less common conditions can also be of non-cardiac medical conditions during a PHE would include an appropriate medical history (Table A physical examination and selected (Table should that are recommended are 1) and and 2) tests for iron to best medical these elements should be in the PHE to assess elite athletes for the presence of non-cardiac medical in sport is defined as a the by traumatic et al 2002). in the from to per related to sport and and for and There is evidence that are particularly in sport IOC and members of the consensus group in the recent Consensus on in (McCrory et al and and A conference was after the of the of including development of The specific evidence and are in detail in the by et al is that a history is an important of the PHE, and should include specific purpose in such a history may identify athletes that into a high risk and an opportunity for the to the athlete in regard to the of in Group (McCrory et al discussion and general agreement on the of assessment during the PHE in high risk sports. The is to provide a comparison point for possible future injury testing. a specific for examination in the PHE was not in the consensus one of the future in research was the assessment where no assessment has been (McCrory et al health

Topic: Cardiovascular Effects of Exercise
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences